Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926330 | 0.84 | — | — | |
| SCHEMBL307237 | 0.84 | — | — | |
| SCHEMBL6791370 | 0.81 | HDAC3 (0.40) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Phosphine SCHEMBL28012772 | 0.81 | — | — | |
| Alcohol SCHEMBL1518044 | 0.78 | — | — | |
| Succinic Acid SCHEMBL30439824 | 0.78 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL28781421 | 0.78 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL28225651 | 0.78 | LMNA (0.64) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL992031 | 0.78 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL27781935 | 0.76 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062423-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. | 2026-03-05 | — | — | US | disclosed |
| EP-3964237-B1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMA (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12378258-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | REGENERON PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-2968593-B1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20220332729-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11345715-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | REGENERON PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3964237-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | Regeneron Pharmaceuticals, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345715-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | CD47, CD44, ACP1 | FFAR3 3934/4885HDAC3 1146/4885HDAC1 396/4885 |
| US-20260062423-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | CD47, EPCAM, CD22 | FFAR3 1158/4885HDAC3 1022/4885HDAC1 1070/4885 |
| US-20220332729-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | CD47, CD44, ACP1 | FFAR3 3934/4885HDAC3 1146/4885HDAC1 396/4885 |
| US-12378258-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | CD47, CD44, ACP1 | FFAR3 3934/4885HDAC3 1146/4885HDAC1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.